Literature DB >> 6526563

Nifedipine in scleroderma ulcerations.

T Y Woo, R C Wong, J P Campbell, M T Goldfarb, J J Voorhees, J P Callen.   

Abstract

Cutaneous ulcerations may be due to a variety of causes, including vasculitis, infections, arterial insufficiency, and microvascular damage. The net effect is diminished blood flow to the skin. Nifedipine, a calcium antagonist, has been shown to improve cutaneous blood flow and to alleviate reactive vasospastic ischemia (Raynaud's phenomenon). The authors report an ischemic ulcer of scleroderma showing visible improvement with nifedipine therapy.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6526563     DOI: 10.1111/j.1365-4362.1984.tb01233.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  3 in total

Review 1.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

Review 2.  Management of Raynaud's phenomenon. Focus on newer treatments.

Authors:  S Roath
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

3.  Impact of topical nifedipine on wound healing in animal model (pig).

Authors:  Augusto Cézar Lacerda Brasileiro; Dinaldo Cavalcanti de Oliveira; Pollianne Barbosa da Silva; João Kairo Soares de Lima Rocha
Journal:  J Vasc Bras       Date:  2020-07-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.